Greene John
- SEC CIK
- 0001610732
No open-market purchases or sales filed in the past year.
Current role at each company
- CRSP CRISPR Therapeutics AGDirectoras of Jun 9, 2026
- NOC Northrop Grumman CorpCVP & Chief Financial Officeras of Feb 13, 2026
- DFS Discover Financial ServicesEVP, Chief Financial Officeras of May 19, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Greene John as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CRSP CRISPR Therapeutics AG
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 (view filing) | Feb 26 | 2 days | Greene JohnDirector | PPurchase | +7.00K | $44.85 | +$313.9K | New position7.00K after |
DFS Discover Financial Services
EVP, Chief Financial Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2024 (view filing) | Jan 26 | 4 days | Greene JohnEVP, Chief Financial Officer | SSale | −35.2K | $106.51 | −$3.75M | −65.4%18.6K after | |
| Feb 17, 2022 (view filing) | Feb 15 | 2 days | Greene JohnEVP, Chief Financial Officer | SSale | −4.44K | $127.95 | −$568.5K | −14.3%26.6K after |